Official Title
Pilot Study: Ketogenic Diet as Protective Factor During SARS-CoV-2 Infection
Brief Summary

The novel coronavirus disease (COVID-19) is posing a serious challenge to the health-care systems worldwide, with an enormous impact on health conditions and loss of lives. More than 30 millions of recoveries worldwide were registered at the end of October 2020 with more than 1 million of deaths. As the disease continues to spread, strategies aimed to reduce hospitalization time in sub intensive unit care, thus reducing pressure on health system, but also to reduce some of the pathological features of COVID-19 such as inflammation and the "cytokines storm". The ketogenic diet is a high fat, low carbohydrate, adequate-protein diet that promotes a physiological ketosis (due to an increase of liver ketone bodies production). High fat, low carbohydrate diets have been shown to reduce duration of ventilator support and partial pressure carbon dioxide in patients with acute respiratory failure. Moreover, the physiological increase in plasma levels of ketone bodies exerts important anti-inflammatory and immunomodulating effects, which may reveal as precious tools to reduce potential adverse outcomes of COVID-19 disease. The hypothesis of this study is that the administration of a ketogenic diet will improve gas exchange, reduce inflammation, and the duration of hospitalization. The plan is to enrol 28 patients with diagnosis of COVID-19 hospitalized but not in ICU with SPO2 higher than 88%.

Unknown status
COVID19

Dietary Supplement: Ketogenic diet with phytoextracts

Patients were provided with an individualized nutritional ketogenic plan during hospitalization

Eligibility Criteria

Inclusion Criteria:

- Patients hospitalized Hospital with COVID-19 diagnosis (nasopharyngeal and
oropharyngeal swab)

- peripheral oxygen saturation higher tha 88%

Exclusion Criteria:

- intensive unit care

- under forced ventilation

- peripheral oxygen saturation lower than 88%

- parenteral nutrition

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 100 Years
Countries
Italy
Locations

Ospedale San Bortolo
Vicenza, Italy

Investigator: Lorenzo Cenci, MD
Contact: +393485405665

Contacts

Antonio Paoli, MD
+393338911322
antonio.paoli@unipd.it

Antonio Paoli, MD, Principal Investigator
University of Padova

San Bortolo Hospital - Vicenza
NCT Number
Keywords
inflammation
CYTOKINES
SARS-CoV-2
ketogenic diet
ketosis
MeSH Terms
COVID-19